JP2010529196A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529196A5
JP2010529196A5 JP2010512186A JP2010512186A JP2010529196A5 JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5 JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/007331 external-priority patent/WO2008156632A1/en
Publication of JP2010529196A publication Critical patent/JP2010529196A/ja
Publication of JP2010529196A5 publication Critical patent/JP2010529196A5/ja
Pending legal-status Critical Current

Links

JP2010512186A 2007-06-12 2008-06-12 アザペプチド誘導体 Pending JP2010529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Publications (2)

Publication Number Publication Date
JP2010529196A JP2010529196A (ja) 2010-08-26
JP2010529196A5 true JP2010529196A5 (US20080242721A1-20081002-C00053.png) 2011-08-04

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512186A Pending JP2010529196A (ja) 2007-06-12 2008-06-12 アザペプチド誘導体

Country Status (26)

Country Link
US (4) US20090036357A1 (US20080242721A1-20081002-C00053.png)
EP (3) EP2003120B9 (US20080242721A1-20081002-C00053.png)
JP (1) JP2010529196A (US20080242721A1-20081002-C00053.png)
KR (2) KR101185899B1 (US20080242721A1-20081002-C00053.png)
CN (2) CN102424668A (US20080242721A1-20081002-C00053.png)
AR (1) AR066972A1 (US20080242721A1-20081002-C00053.png)
AT (2) ATE447554T1 (US20080242721A1-20081002-C00053.png)
AU (1) AU2008267048C1 (US20080242721A1-20081002-C00053.png)
BR (2) BRPI0813911A2 (US20080242721A1-20081002-C00053.png)
CA (1) CA2692028C (US20080242721A1-20081002-C00053.png)
CO (1) CO6241121A2 (US20080242721A1-20081002-C00053.png)
CY (1) CY1109766T1 (US20080242721A1-20081002-C00053.png)
DE (1) DE602008000255D1 (US20080242721A1-20081002-C00053.png)
DK (1) DK2003120T3 (US20080242721A1-20081002-C00053.png)
ES (3) ES2356334T3 (US20080242721A1-20081002-C00053.png)
HK (2) HK1136576A1 (US20080242721A1-20081002-C00053.png)
HR (1) HRP20100065T1 (US20080242721A1-20081002-C00053.png)
MX (1) MX2009013565A (US20080242721A1-20081002-C00053.png)
PL (1) PL2003120T3 (US20080242721A1-20081002-C00053.png)
PT (1) PT2003120E (US20080242721A1-20081002-C00053.png)
RS (1) RS51226B (US20080242721A1-20081002-C00053.png)
RU (2) RU2448958C2 (US20080242721A1-20081002-C00053.png)
SI (1) SI2003120T1 (US20080242721A1-20081002-C00053.png)
TW (1) TW200908970A (US20080242721A1-20081002-C00053.png)
WO (1) WO2008156632A1 (US20080242721A1-20081002-C00053.png)
ZA (1) ZA200909079B (US20080242721A1-20081002-C00053.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
WO2008156632A1 (en) 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
EP2334318B1 (en) * 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
US8784858B2 (en) * 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
HRP20211687T1 (hr) * 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
AR117600A1 (es) * 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206497B1 (en) 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
KR100333016B1 (ko) 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
ATE282428T1 (de) 2001-05-03 2004-12-15 Hoffmann La Roche Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2458807A1 (en) * 2001-08-31 2003-03-13 Bristol-Myers Squibb Company Use of atazanavir in hiv therapy
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CA2516642C (en) 2003-02-21 2010-11-23 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CA2571726C (en) * 2004-07-06 2013-05-21 Abbott Laboratories Prodrugs of hiv protease inhibitors
CN101076319A (zh) 2004-09-29 2007-11-21 科迪斯公司 稳定的非晶形雷帕霉素样化合物的药物剂型
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Similar Documents

Publication Publication Date Title
JP2010529196A5 (US20080242721A1-20081002-C00053.png)
JP2012111758A5 (US20080242721A1-20081002-C00053.png)
JP2012107057A5 (US20080242721A1-20081002-C00053.png)
JP2011518833A5 (US20080242721A1-20081002-C00053.png)
JP2011510079A5 (US20080242721A1-20081002-C00053.png)
JP2006515626A5 (US20080242721A1-20081002-C00053.png)
JP2009535462A5 (US20080242721A1-20081002-C00053.png)
JP2007269812A5 (US20080242721A1-20081002-C00053.png)
JP2009149903A5 (US20080242721A1-20081002-C00053.png)
JP2013532130A5 (US20080242721A1-20081002-C00053.png)
JP2011105738A5 (US20080242721A1-20081002-C00053.png)
JP2011508438A5 (US20080242721A1-20081002-C00053.png)
JP2010501534A5 (US20080242721A1-20081002-C00053.png)
JP2010019854A5 (US20080242721A1-20081002-C00053.png)
JP2010536766A5 (US20080242721A1-20081002-C00053.png)
JP2011519871A5 (US20080242721A1-20081002-C00053.png)
JP2013500371A5 (US20080242721A1-20081002-C00053.png)
JP2012514009A5 (US20080242721A1-20081002-C00053.png)
JP2013173782A5 (US20080242721A1-20081002-C00053.png)
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
JP2008188757A5 (US20080242721A1-20081002-C00053.png)
JP2009504909A5 (US20080242721A1-20081002-C00053.png)
JP2006305390A5 (US20080242721A1-20081002-C00053.png)
JP2010241791A5 (US20080242721A1-20081002-C00053.png)
JP2011037885A5 (US20080242721A1-20081002-C00053.png)